Filter Results
:
(178)
Show Results For
-
All HBS Web
(178)
- People (1)
- News (53)
- Research (81)
- Events (3)
- Multimedia (9)
- Faculty Publications (50)
Show Results For
-
All HBS Web
(178)
- People (1)
- News (53)
- Research (81)
- Events (3)
- Multimedia (9)
- Faculty Publications (50)
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more...
View Details
Keywords:
Valuation;
Cash Flow;
Financing and Loans;
Business Startups;
Financial Strategy;
Medical Devices and Supplies Industry;
Pharmaceutical Industry;
Health Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- May 2017
- Other Article
Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis
By: Andrew Hill, Po-Ru Loh, Ragu B. Bharadwaj, Pascal Pons, Jingbo Shang, Eva C. Guinan, Karim R. Lakhani, Iain Kilty and Scott Jelinsky
BACKGROUND:
The association of differing genotypes with disease-related phenotypic traits offers great potential to both help identify new therapeutic targets and support stratification of patients who would gain the greatest benefit from specific drug classes....
View Details
Keywords:
Crowdsourcing;
Genome-wide Association Study;
Logistic Regression;
Open Innovation;
PLINK;
Collaborative Innovation and Invention
Hill, Andrew, Po-Ru Loh, Ragu B. Bharadwaj, Pascal Pons, Jingbo Shang, Eva C. Guinan, Karim R. Lakhani, Iain Kilty, and Scott Jelinsky. "Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis." GigaScience 6, no. 5 (May 2017).
- Article
Sustainability, Business, and Health
By: George Serafeim, Amanda M. Rischbieth and Howard K. Koh
The coronavirus disease 2019 (COVID-19) pandemic has demonstrated that response demands involvement from every sector of society. As a major example, some businesses have stepped up in ways previously unimaginable. Garment companies have repurposed production to face...
View Details
Keywords:
COVID;
COVID-19;
Sustainability;
Health And Wellness;
Corporate Social Responsibility;
Health Pandemics;
Health;
Corporate Social Responsibility and Impact;
Corporate Accountability;
Health Care and Treatment
Serafeim, George, Amanda M. Rischbieth, and Howard K. Koh. "Sustainability, Business, and Health." JAMA, the Journal of the American Medical Association 324, no. 2 (July 14, 2020): 147–148.
- Web
Curriculum - MBA
this course is to enable students to explore entrepreneurship within the life sciences. Students will explore opportunities along various aspects of the R&D and commercialization lifecycle, along science, clinical, regulatory and commercial areas of the lifecycle....
View Details
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at...
View Details
Wells, John R., and Benjamin Weinstock. "Minerva 2010: Turbulent Times." Harvard Business School Case 721-390, September 2020.
- Web
Faculty & Advisors - MBA
Representative investments include Semma Therapeutics (acquired by Vertex Pharmaceuticals), Korro Bio, Akouos (NASDAQ: AKUS), Gemini Therapeutics (NASDAQ: GMTX), Inipharm, and PACT Pharma. She was previously...
View Details
- Web
Overview - MBA
relevant timeframes, opportunity-costs, rewards, and organizational behavior. Assess the potential therapeutic value of discoveries emanating from lab-discovery in the life sciences and understand ways to accelerate these discoveries into...
View Details
- Web
Capstone - MBA
that will advance new drug discoveries and therapeutics with those equally passionate about changing the business of healthcare for the better. 2 The practicalities of business decisions meet the practicalities of hard science. Students...
View Details
- 12 Jul 2016
- First Look
July 12, 2016
spending. Whereas traditional (small-molecule) drugs have historically faced price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already...
View Details
Keywords:
Sean Silverthorne
- 01 Nov 2013
- HBS Seminar
Eric Olson, Chief Scientific Officer at Syros Pharmaceuticals
- Web
Hiring Organizations
Cargill Carlyle Group, The Carrum Health Cartesian Capital Group Casa Verde Capital Causeway Capital Management Causeway Media Partners CAVA CBRE CBRE Global Investors Celonis Centerview Partners CenterWell Home Health Centroid Investment Partners Cepheid Cha View Details
- May 2024
- Article
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
By: Caroline Marra and Ariel D. Stern
Digital health technologies (DHTs) can enable more patient-centric therapeutic development by generating evidence that captures how patients feel and function, enabling decentralized trial designs that increase participant inclusivity and convenience, and collecting...
View Details
Keywords:
Health Care and Treatment;
Technological Innovation;
Product Development;
Health Testing and Trials;
Governing Rules, Regulations, and Reforms
Marra, Caroline, and Ariel D. Stern. "Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms." Clinical Pharmacology & Therapeutics 115, no. 5 (May 2024): 988–992.
- 11 Oct 2011
- Working Paper Summaries
US Healthcare Reform and the Pharmaceutical Industry
- Web
Blavatnik Fellowship in Life Science Entrepreneurship - Health Care
venture capital firm. Since 2002, Peter has been involved in the creation of several novel therapeutic and drug discovery platform companies. Prior to Atlas he was co-founder, executive vice president, and chief business officer of Celera...
View Details
- Web
Named Fellowship Funds - Alumni
Institute for Translational Medicine and Therapeutics at the School of Medicine of the University of Pennsylvania and on the board of Hope for New York. He received a BS in economics from the Wharton School of the University of...
View Details
- Web
Technology & Innovation - Faculty & Research
Technologies in Clinical Trials by Pharmaceutical and Medical Device FirmsBy: Caroline Marra and Ariel D. Stern May 2024 | Article | Clinical Pharmacology & Therapeutics Digital health technologies (DHTs) can enable more patient-centric...
View Details
- 01 Dec 2023
- News
Wide Horizon
There were three critical events that led John Rodakis (MBA 1997) to form the nonprofit N of One in 2014 and ultimately dedicate his life to surfacing breakthrough autism research. The first occurred on Thanksgiving of 2012. He had driven about four hours with his wife...
View Details
Keywords:
Dan Morrell; Photos by Sarah Wilson
- Web
Health Care - Faculty & Research
approaches in developing nations can impact global health. Recent Publications Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device FirmsBy: Caroline Marra and Ariel D. Stern May 2024 | Article | Clinical Pharmacology &...
View Details
- Web
Mental Health - MBA
workers, psychologists, and psychiatrists who maintain private practices in the Harvard Square area and accept the student health insurance. These clinicians typically work with students who have an interest in a long-term therapeutic...
View Details
- 01 Dec 2023
- News
Drop Everything, Read This
The Bookshelf Rick Rubin is one of the greatest music producers of all time. His book, The Creative Act: A Way of Being, is about the creative process and is based on his experiences with era-defining musicians. He encourages the reader to be open to clues and...
View Details